Ranbaxy April-June net down over 25 per cent at Rs243 crore

Ranbaxy Laboratories has reported a consolidated net profit (after tax and minority interest) of Rs243.24 crore for the quarter ended 30 June 2011, down 25.4 per cent from Rs325.71 crore during the quarter ended 30 June 2010.

Total group income has decreased to Rs2,172.26 crore for the April-June 2011 quarter from Rs2,270.07 crore during the quarter ended 30 June 2010, unaudited figures released by the company showed.

Consolidated net sales during April-June 2011 stood at Rs2,059.3 crore ($461 million) against sales of Rs2,095.3 crore ($456 million) during the same quarter of the previous year, registering a negative growth of (-) 18 per cent year-on-year.

Earnings before interest, tax, depreciation and amortisation (EBITDA) was 10 per cent of sales at Rs213.5 crore ($48 million) during April-June 2011 against an EBDTA of Rs416.8 crore ($91 million) during the previous year quarter.

Profit after tax (PAT) stood at Rs243.2 crore ($54 million) during the April-June 2011 quarter against Rs325.7 crore ($71 million) during the similar quarter of the previous year.

For the first half ended 30 June 2011, Ranbaxy reported consolidated net sales of Rs4,205.6 crore ($935 million) against H1-'10 consolidated net sales of Rs4,579.1 crore ($996 million), registering a net decline in sales of (-)16 per cent.